ABBV Nov 2024 170.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 12:20PM EDT. Market open.
| Previous close | 24.65 |
| Open | 24.50 |
| Bid | 24.60 |
| Ask | 25.35 |
| Strike | 170.00 |
| Expiry date | 2024-11-15 |
| Day's range | 24.18 - 24.83 |
| Contract range | N/A |
| Volume | |
| Open interest | 543 |
Investor's Business Daily2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
Pharmaceutical stocks largely shook off the brunt of negotiated drug prices. But that doesn't mean they'll be spared election noise.
Simply Wall St.AbbVie (NYSE:ABBV) Expands Eye Care Portfolio with Ripple Therapeutics Collaboration, Boosts Growth Potential
AbbVie(NYSE:ABBV) is navigating a period of significant developments, including a robust 4% increase in operational sales and strategic acquisitions to bolster its pipeline. However, challenges such as declining profit margins and competitive pressures persist. In the discussion that follows, we will explore AbbVie's core strengths, critical weaknesses, growth opportunities, and key threats to provide a comprehensive overview of the company's current business situation.
- Simply Wall St.
AbbVie Inc. (NYSE:ABBV) is largely controlled by institutional shareholders who own 73% of the company
Key Insights Institutions' substantial holdings in AbbVie implies that they have significant influence over the...
© 2024 Yahoo. All rights reserved.